{
    "symbol": "XNCR",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-03 23:28:10",
    "content": " For our PD-1 CTLA-4 bispecific, vudalimab, will also present some early data from the first of our two Phase II studies, the chemotherapy combination in patients with metastatic castrate-resistant prostate cancer and our second Phase II study in patients with clinically defined high-risk metastatic castrate-resistant prostate cancer and certain gynecological malignancies is now dosing patients. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. Your line is now open. We think that again, it's not really going to be that different in terms of the potential or the insights on the readout from the different cohorts of chemo receiving patients, certainly, the PARP inhibitor receiving patients, those that have DNA damage repair deficiencies are sort of a separate category."
}